Putting the latest drug trends and insights at your fingertips

As COVID-19 continues to impact the Canadian economy and strain health care resources, these times call for a critical re-think of health care services and benefit plans, and part of the Green Shield Canada (GSC) approach continues to be building rigorously-tested solutions that increase the value of drug spend.

To shed further light on our industry’s drug landscape, HBM+, a division of GSC, has released its inaugural national Drug Trends and Strategic Insights report, which examines the latest drug directions and trends, from the use of opioids and biosimilars to the evolving approaches to reimbursing health care professionals.

The report, which includes data from GSC Group clients as well as other HBM+ partners, also highlights tangible cost management and health improvement solutions for plan sponsors and advisors – many of which will be familiar to you – and provides a glimpse of the future, including the impact of pharmacogenomics and the potential of gene therapy strategies.

LEARN MORE...

Click here to view the report, and contact your GSC account team if you have any questions.